Clinical Trial Update: ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas [Phase 2]

View source ↗

Summary

Phase 2 study ARTEMIS-002 (HS-20093) is evaluating HS-20093 in patients with relapsed or refractory osteosarcoma and other sarcomas; the trial is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma
• Sarcoma

Drugs mentioned

• HS-20093

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: Osteosarcoma, Sarcoma | Phase 2 | Status: RECRUITING